Danish biotechnology company at Copenhagen, founded in 2017 on work from the University of Copenhagen, which develops antibody drug conjugates against targets found in solid tumours. Its lead candidate is directed at the uPARAP receptor for soft tissue sarcoma and other cancers with few treatment options, and it builds a wider conjugate pipeline funded by international venture investors.
No hay comentarios disponibles.
Deja tu valoración & comentario